NasdaqCM:CELC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. More Details


Snowflake Analysis

Flawless balance sheet with moderate growth potential.

Share Price & News

How has Celcuity's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CELC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: CELC's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

12.7%

CELC

4.5%

US Biotechs

0.6%

US Market


1 Year Return

-6.8%

CELC

26.3%

US Biotechs

22.7%

US Market

Return vs Industry: CELC underperformed the US Biotechs industry which returned 27.2% over the past year.

Return vs Market: CELC underperformed the US Market which returned 21% over the past year.


Shareholder returns

CELCIndustryMarket
7 Day12.7%4.5%0.6%
30 Day73.3%14.1%13.1%
90 Day83.6%10.5%4.5%
1 Year-6.8%-6.8%28.4%26.3%25.5%22.7%
3 Year-45.5%-45.5%27.3%20.7%49.0%39.1%
5 Yearn/a15.3%7.4%98.3%76.5%

Long-Term Price Volatility Vs. Market

How volatile is Celcuity's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Celcuity undervalued compared to its fair value and its price relative to the market?

7.44x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CELC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CELC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CELC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CELC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CELC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CELC is overvalued based on its PB Ratio (7.4x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Celcuity forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

49.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CELC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: CELC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CELC's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if CELC's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CELC's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CELC's Return on Equity is forecast to be high in 3 years time


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Celcuity performed over the past 5 years?

-20.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CELC is currently unprofitable.

Growing Profit Margin: CELC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CELC is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.

Accelerating Growth: Unable to compare CELC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CELC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: CELC has a negative Return on Equity (-63.45%), as it is currently unprofitable.


Next Steps

Financial Health

How is Celcuity's financial position?


Financial Position Analysis

Short Term Liabilities: CELC's short term assets ($14.0M) exceed its short term liabilities ($1.0M).

Long Term Liabilities: CELC's short term assets ($14.0M) exceed its long term liabilities ($116.8K).


Debt to Equity History and Analysis

Debt Level: CELC is debt free.

Reducing Debt: CELC had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CELC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CELC has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 19.1% each year.


Next Steps

Dividend

What is Celcuity current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CELC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CELC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CELC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CELC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CELC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.1yrs

Average management tenure


CEO

Brian Sullivan (58 yo)

8.83yrs

Tenure

US$991,544

Compensation

Mr. Brian F. Sullivan is a Co-Founder of Celcuity Inc. and has been its Chairman and Chief Executive Officer since 2012 and served as its Chief Financial Officer. Mr. Sullivan co-founded Entegris, Inc. in ...


CEO Compensation Analysis

Compensation vs Market: Brian's total compensation ($USD991.54K) is above average for companies of similar size in the US market ($USD561.31K).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Brian Sullivan
Co-Founder8.83yrsUS$991.54k26.76%
$ 27.4m
Lance Laing
Co-Founder8.83yrsUS$991.30k12.14%
$ 12.4m
Vicky Hahne
Chief Financial Officer3.33yrsUS$205.19k0.052%
$ 52.9k
Eric Lindquist
Chief Business Officer1.17yrsno datano data

6.1yrs

Average Tenure

58yo

Average Age

Experienced Management: CELC's management team is seasoned and experienced (6.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Brian Sullivan
Co-Founder8.83yrsUS$991.54k26.76%
$ 27.4m
Lance Laing
Co-Founder8.83yrsUS$991.30k12.14%
$ 12.4m
Richard Nigon
Independent Director3.83yrsUS$75.00k1.07%
$ 1.1m
David Dalvey
Independent Director6.75yrsUS$75.00k0.076%
$ 78.0k
Leo Furcht
Independent Director1.5yrsUS$75.00k0%
$ 0
Ronald McGlennen
Member of Scientific Advisory Boardno datano datano data
Edward Greeno
Member of Scientific Advisory Boardno datano datano data
Sara Hurvitz
Member of Scientific Advisory Boardno datano datano data
Carol Lange
Member of Scientific Advisory Boardno datano datano data
Benita Katzenellenbogen
Member of Scientific Advisory Boardno datano datano data
John Katzenellengogen
Member of Scientific Advisory Boardno datano datano data
Mothaffar Rimawi
Member of Scientific Advisory Board1.83yrsno datano data

5.3yrs

Average Tenure

62yo

Average Age

Experienced Board: CELC's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Celcuity Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Celcuity Inc.
  • Ticker: CELC
  • Exchange: NasdaqCM
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$102.455m
  • Shares outstanding: 10.30m
  • Website: https://www.celcuity.com

Number of Employees


Location

  • Celcuity Inc.
  • 16305–36th Avenue North
  • Suite 100
  • Minneapolis
  • Minnesota
  • 55446
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CELCNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDSep 2017

Biography

Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company’s CELsignia diagnostic platform uses a patien...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/02 00:21
End of Day Share Price2020/12/01 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.